Last reviewed · How we verify
NCT05793502
Study on Effectiveness and Safety of LBBaP With Solia S and Selectra 3D Developed by BIOTRONIK
trial testing Solia S and Selectra 3D Developed by BIOTRONIK in Consented to Participate in the Trial and Signed an ICF in 1,000 participants. Currently enrolling.
20 April 2025
Quick facts
| Lead sponsor | Chinese Academy of Medical Sciences, Fuwai Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 4 July 2023 |
| Primary completion | 20 April 2025 |
| Estimated completion | 20 April 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Solia S and Selectra 3D Developed by BIOTRONIK
Conditions studied
- Consented to Participate in the Trial and Signed an ICF — all drugs for Consented to Participate in the Trial and Signed an ICF →
- Patients With an Indication for PM Implantation or CRTP — all drugs for Patients With an Indication for PM Implantation or CRTP →
Sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
Who can join
18 and older, any sex, with Consented to Participate in the Trial and Signed an ICF or Patients With an Indication for PM Implantation or CRTP. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is aimed to assess the effectiveness and safety of LBBaP with Solia S and Selectra 3D in the Chinese population by analyzing the operation success rate and the system stability during follow-up visits.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Is Conduction System Pacing a Valuable Alternative to Biventricular Pacing for Cardiac Resynchronization Therapy?
Castagno D, Zanon F, Pastore G, De Ferrari GM, et al · · 2024 · cited 2× · PMID 38786966 · DOI 10.3390/jcdd11050144
Verify or expand the search:
- PubMed search for NCT05793502
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Chinese Academy of Medical Sciences, Fuwai Hospital trials
Trials by the same sponsor.
- NCT07450196 — A Prospective, Multicenter, Observational Study Evaluating Safety and Effectiveness of SAPIEN 3 Transcatheter Aortic Val · not yet recruiting
- NCT07511309 — FFR-Guided Revascularization in Atherosclerotic Renal Artery Stenosis: A Randomized Controlled Trial · NA · not yet recruiting
- NCT07054541 — A Novel Echocardiography-Guided Strategy for Percutateous Closure of Atrial Septal Defect Assisted by PannaWire · Phase 4 · not yet recruiting
- NCT07458672 — TAVR for Aortic Regurgitation Under TTE Guidance · NA · not yet recruiting
- NCT07462325 — Proteomic and Inflammatory Omics Changes With Colchicine Therapy in Coronary Heart Disease · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05793502 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese Academy of Medical Sciences, Fuwai Hospital
- Last refreshed: 26 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05793502.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing